Inito Secures $29M to Power At-Home Health Tests with AI-Designed Antibodies

Fertility startup Inito has raised $29 million in new funding. The Series B round was led by Bertelsmann India Investments and Fireside Ventures. This brings the company’s total funding to approximately $45 million.

The capital will scale its at-home diagnostics platform globally. More importantly, it fuels a novel tech bet. Inito is investing heavily in AI-engineered antibodies to create a new generation of home tests.

From Fertility Tracker to Broader Health Platform

Inito first launched its fertility monitor in 2021. Its device measures multiple hormones like estrogen and progesterone on one strip. The company has analyzed over 30 million fertility hormone data points since then.

Now, it aims to evolve into a comprehensive health diagnostics platform. The funding will support tests for pregnancy and menopause monitoring. It also plans expansion into new international markets beyond the United States.

Company leadership sees this as a fundamental shift. The goal is to move beyond just “trying to conceive” support. They envision a platform for lifetime hormone health tracking from home.

The AI Antibody Breakthrough Behind the Vision

The core of Inito’s new strategy is its antibody design process. Traditional antibodies for tests are grown in animals. This method is slow, expensive, and can lack sensitivity for home use.

Inito’s AI changes the game entirely. “We design synthetic antibodies using AI and test millions of variants virtually,” explained CTO Varun Venkatesan. This process creates more sensitive and stable antibodies than traditional methods.

This technological leap is key to unlocking new kinds of tests. According to industry reports, such innovation could drastically improve at-home diagnostic accuracy. It allows for measuring a wider range of biomarkers with lab-grade confidence from home.

Inito’s $29 million funding round marks a pivotal investment in the future of decentralized healthcare. By leveraging AI-designed antibodies, the company is positioning itself to redefine home diagnostics. This move could make personalized, proactive health monitoring accessible to millions globally.

A quick knowledge drop for you

What does Inito’s device actually measure?

Inito’s current fertility monitor measures four key hormones on a single test strip. It tracks estrogen, Luteinizing Hormone (LH), progesterone metabolite PdG, and Follicle-Stimulating Hormone (FSH). This combination helps predict fertile days and confirm ovulation.

How are AI-designed antibodies different?

Unlike antibodies grown in animals, AI-designed antibodies are created digitally. Scientists use software to predict protein structures and design synthetic versions. This leads to more sensitive, consistent, and stable antibodies for more accurate tests.

What will the new funding be used for?

The $29 million will fund three main areas. It will scale manufacturing and global expansion. It will accelerate research into AI-engineered antibodies. Finally, it will develop new tests for pregnancy, menopause, and broader health monitoring.

Is Inito moving away from fertility tracking?

No, fertility remains a core offering. The company is expanding its platform to include more health stages. The vision is a single device and app that can support users through conception, pregnancy, menopause, and general wellness.

Who led this investment round?

The Series B funding round was co-led by Bertelsmann India Investments and Fireside Ventures. These are established venture firms with strong track records in healthcare and consumer technology investments.